ESC 365 - Titration process and predictors of achieving target dose of sacubitril/valsartan in patients with chronic heart failure and reduced ejection fraction attending to an outpatient heart failure clinic.

HFA Premium Access

Titration process and predictors of achieving target dose of sacubitril/valsartan in patients with chronic heart failure and reduced ejection fraction attending to an outpatient heart failure clinic.

Session: Poster Session 3 - Chronic Heart Failure – Treatment

Topic: Pharmacotherapy

Speaker: Doctor M. Rizzo (Sabadell, ES)

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Doctor Marcelo Rizzo

Hospital Universitari Parc Tauli de Sabadell, Sabadell (Spain)

0 follower

56 more presentations in this session

Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.

Speaker: Doctor L. Buttigieg (Msida, MT)

Sacubitril valsartan, a multicentric experience

Speaker: Mr F. Cortes (Sevilla, ES)

Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy

Speaker: Professor B. Kanazirev (Varna, BG)

Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy

Speaker: Associate Professor C. Hsu (Taipei, TW)

Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy

Speaker: Doctor C. Hsieh (Taipei, TW)

Access the full session

Poster Session 3 - Chronic Heart Failure – Treatment

Speakers: Doctor M. Rizzo, Doctor L. Buttigieg, Mr F. Cortes, Professor B. Kanazirev, Associate Professor C. Hsu...

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources